192 related articles for article (PubMed ID: 15655717)
21. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
[TBL] [Abstract][Full Text] [Related]
22. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.
Brubaker PL; Drucker DJ
Endocrinology; 2004 Jun; 145(6):2653-9. PubMed ID: 15044356
[TBL] [Abstract][Full Text] [Related]
23. Physiology of GLP-1--lessons from glucoincretin receptor knockout mice.
Thorens B
Horm Metab Res; 2004; 36(11-12):766-70. PubMed ID: 15655706
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
25. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.
Gromada J; Holst JJ; Rorsman P
Pflugers Arch; 1998 Apr; 435(5):583-94. PubMed ID: 9479010
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide.
Stanley S; Wynne K; Bloom S
Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G693-7. PubMed ID: 15068960
[TBL] [Abstract][Full Text] [Related]
27. The physiology of glucagon-like peptide 1.
Holst JJ
Physiol Rev; 2007 Oct; 87(4):1409-39. PubMed ID: 17928588
[TBL] [Abstract][Full Text] [Related]
28. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
29. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress.
Bojanowska E
Med Sci Monit; 2005 Aug; 11(8):RA271-8. PubMed ID: 16049395
[TBL] [Abstract][Full Text] [Related]
30. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.
Drucker DJ; Lovshin J; Baggio L; Nian M; Adatia F; Boushey RP; Liu Y; Saleh J; Yusta B; Scrocchi L
Ann N Y Acad Sci; 2000; 921():226-32. PubMed ID: 11193827
[TBL] [Abstract][Full Text] [Related]
31. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.
Nakade Y; Tsukamoto K; Pappas TN; Takahashi T
Brain Res; 2006 Sep; 1111(1):117-21. PubMed ID: 16884700
[TBL] [Abstract][Full Text] [Related]
32. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
Drucker DJ
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
[TBL] [Abstract][Full Text] [Related]
33. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
34. [Glucagon-like peptide-1: pleiotropic effects on the cardiovascular system].
Avogaro A
G Ital Cardiol (Rome); 2008 Nov; 9(11):753-8. PubMed ID: 19058666
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, secretion and biological actions of the glucagon-like peptides.
Lovshin J; Drucker DJ
Pediatr Diabetes; 2000 Mar; 1(1):49-57. PubMed ID: 15016242
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide 1 (GLP-1) and eating.
Gutzwiller JP; Degen L; Heuss L; Beglinger C
Physiol Behav; 2004 Aug; 82(1):17-9. PubMed ID: 15234584
[TBL] [Abstract][Full Text] [Related]
37. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY?
Beglinger C; Degen L
Physiol Behav; 2006 Nov; 89(4):460-4. PubMed ID: 16828127
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site.
Hay CW; Sinclair EM; Bermano G; Durward E; Tadayyon M; Docherty K
J Endocrinol; 2005 Aug; 186(2):353-65. PubMed ID: 16079261
[TBL] [Abstract][Full Text] [Related]
40. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
Hui H; Zhao X; Perfetti R
Diabetes Metab Res Rev; 2005; 21(4):313-31. PubMed ID: 15852457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
